Drug burden index in older adults: Theoretical and practical issues

Clinical Interventions in Aging

Volumn 9, Issue , 2014, Pages 1503-1515

  Kouladjian, Lisa ^a   Gnjidic, Danijela ^a,b   Chen, Timothy F ^b   Mangoni, Arduino A ^c   Hilmer, Sarah N ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Anticholinergics; Deprescribing; Drug burden index; High risk prescribing; Older adults; Pharmacological risk assessment tools; Sedative medications

Indexed keywords

AMITRIPTYLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOXEPIN; OLANZAPINE; QUETIAPINE; SEDATIVE AGENT; HYPNOTIC SEDATIVE AGENT;

COGNITION; DRUG BURDEN INDEX; DRUG EXPOSURE; DRUG RESPONSE; HUMAN; INAPPROPRIATE PRESCRIBING; INSOMNIA; MAJOR DEPRESSION; MATHEMATICAL ANALYSIS; MENTAL DISEASE; MORTALITY; POLYPHARMACY; PRESCRIPTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT; AGED; DRUG EFFECTS; MOVEMENT (PHYSIOLOGY); VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHOLINERGIC ANTAGONISTS; COGNITION; HUMANS; HYPNOTICS AND SEDATIVES; INAPPROPRIATE PRESCRIBING; MOVEMENT; POLYPHARMACY;

EID: 84907637657     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S66660     Document Type: Review

References (95)

1. American Pharmacists Association; National Association of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). J Am Pharm Assoc. 2008;48(3):341-353.
2. World Health Organisation. Ageing and life course: interesting facts about ageing. Geneva, Switzerland: World Health Organisation; 2012. Available from: http://www.who.int/ageing/about/facts/en/index.html#. Accessed July 9, 2014.
3. Linjakumpu T, Hartikainen S, Klaukka T, Veijola J, Kivelä S-L, Isoaho R. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol. 2002;55(8):809-817.
4. Wise J. Polypharmacy: a necessary evil. BMJ. 2013;347:f7033.
5. Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin Interv Aging. 2008;3(2): 383-389.
6. Nishtala PS, Fois RA, McLachlan AJ, Bell JS, Kelly PJ, Chen TF. Anticholinergic activity of commonly prescribed medications and neuropsychiatric adverse events in older people. J Clin Pharmacol. 2009;49(10):1176-1184.
7. Rothberg MB, Herzig SJ, Pekow PS, Avrunin J, Lagu T, Lindenauer PK. Association between sedating medications and delirium in older inpatients. J Am Geriatr Soc. 2013;61(6):923-930.
8. Ineke Neutel C, Skurtveit S, Berg C. Polypharmacy of potentially addictive medication in the older persons-quantifying usage. Pharmacoepidemiol Drug Saf. 2012;21(2):199-206.
9. Bell JS, Mezrani C, Blacker N, et al. Anticholinergic and sedative medicines-prescribing considerations for people with dementia. Aust Fam Physician. 2012;41(1-2):45-49.
10. Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council Cognitive Function and Ageing study. J Am Geriatr Soc. 2011;59(8):1477-1483.
11. Koyama A, Steinman M, Ensrud K, Hillier TA, Yaffe K. Long-term cognitive and functional effects of potentially inappropriate medications in older women. J Gerontol A Biol Sci Med Sci. 2014;69(4):423-429.
12. Hilmer S., Mager DE, Simonsick EM, et al. A Drug Burden Index to define the functional burden of medications in older people. Arch Intern Med. 2007;167(8):781-787.
13. Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging. 1993;3(4):335-348.
14. Duran CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol. 2013; 69(7):1485-1496.
15. Taipale HT, Hartikainen S, Bell JS. A comparison of four methods to quantify the cumulative effect of taking multiple drugs with sedative properties. Am J Geriatr Pharmacother. 2010;8(5):460-471.
16. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169.
17. Cancelli I, Beltrame M, Gigli GL, Valente M. Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients. Neurol Sci. 2009;30(2):87-92.
18. Mangoni AA, van Munster BC, Woodman RJ, de Rooij SE. Measures of anticholinergic drug exposure, serum anticholinergic activity, and all-cause postdischarge mortality in older hospitalized patients with hip fractures. Am J Geriatr Psychiatry. 2013;21(8):785-793.
19. Craig D, Passmore AP, Fullerton KJ, et al. Factors influencing prescription of CNS medications in different elderly populations. Pharmacoepidemiol Drug Saf. 2003;12(5):383-387.
20. Kersten H, Wyller TB. Anticholinergic drug burden in older people’s brain-how well is it measured? Basic Clin Pharmacol Toxicol. 2014; 114(2):151-159.
21. Nissen D. Mosby’s Drug Consult. St Louis, MO, USA: Mosby Inc; 2004.
22. Duplay D. Physicians’ Desk Reference. 58th ed. Montvale, NJ, USA: Thomson PDR; 2004.
23. Gnjidic D, Le Couteur DG, Abernethy DR, Hilmer SN. Drug Burden Index and Beers criteria: impact on functional outcomes in older people living in self-care retirement villages. J Clin Pharmacol. 2012;52(2): 258-265.
24. Gnjidic D, Cumming RG, Le Couteur DG, et al. Drug Burden Index and physical function in older Australian men. Br J Clin Pharmacol. 2009;68(1):97-105.
25. Gnjidic D, Bell JS, Hilmer S., Lonnroos E, Sulkava R, Hartikainen S. Drug Burden Index associated with function in community-dwelling older people in Finland: a cross-sectional study. Ann Med. 2012;44(5): 458-467.
26. Wilson NM, Hilmer S., March LM, et al. Associations between Drug Burden Index and physical function in older people in residential aged care facilities. Age Ageing. 2010;39(4):503-507.
27. Gnjidic D, Hilmer S., Blyth FM, et al. High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther. 2012;91(3):521-528.
28. Nishtala PS, Narayan SW, Wang T, Hilmer SN. Associations of Drug Burden Index with falls, general practitioner visits, and mortality in older people. Pharmacoepidemiol Drug Saf. 2014;23(7):753-758.
29. Wilson NM, Hilmer S., March LM, et al. Associations between Drug Burden Index and falls in older people in residential aged care. J Am Geriatr Soc. 2011;59(5):875-880.
30. Wilson NM, Hilmer S., March LM, et al. Associations between Drug Burden Index and mortality in older people in residential aged care facilities. Drugs Aging. 2012;29(2):157-165.
31. Gnjidic D, Hilmer S., Hartikainen S, et al. Impact of high risk drug use on hospitalization and mortality in older people with and without Alzheimer’s disease: a national population cohort study. PLoS One. 2014;9(1):e83224.
32. Gnjidic D, Le Couteur DG, Naganathan V, et al. Effects of Drug Burden Index on cognitive function in older men. J Clin Psychopharmacol. 2012;32(2):273-277.
33. Community Pharmacy Agreement. Medication Management Initiatives. Available from: http://5cpa.com.au/programs/medication-management-initiatives/home-medicines-review/. Accessed July 10, 2013.
34. Castelino RL, Hilmer S., Bajorek BV, Nishtala P, Chen TF. Drug Burden Index and potentially inappropriate medications in community-dwelling older people: the impact of Home Medicines Review. Drugs Aging. 2010;27(2):135-148.
35. Nishtala PS, Hilmer S., McLachlan AJ, Hannan PJ, Chen TF. Impact of residential medication management reviews on Drug Burden Index in aged-care homes: a retrospective analysis. Drugs Aging. 2009;26(8): 677-686.
36. Lantz MS, Giambanco V, Buchalter EN. A ten-year review of the effect of OBRA-87 on psychotropic prescribing practices in an academic nursing home. Psychiatr Serv. 1996;47(9):951-955.
37. Gnjidic D, Le Couteur DG, Abernethy DR, Hilmer SN. A pilot randomized clinical trial utilizing the Drug Burden Index to reduce exposure to anticholinergic and sedative medications in older people. Ann Pharmacother. 2010;44(11):1725-1732.
38. Gnjidic D, Le Couteur DG, Kouladjian L, Hilmer SN. Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clin Geriatr Med. 2012;28(2):237-253.
39. Patterson SM, Hughes C, Kerse N, Cardwell CR, Bradley MC. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2012;5:CD008165.
40. Kaur S, Mitchell G, Vitetta L, Roberts MS. Interventions that can reduce inappropriate prescribing in the elderly: a systematic review. Drugs Aging. 2009;26(12):1013-1028.
41. Durieux P, Trinquart L, Colombet I, et al. Computerized advice on drug dosage to improve prescribing practice. Cochrane Database Syst Rev. 2008;3:CD002894.
42. Garg AX, Adhikari NK, McDonald H, et al. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. JAMA. 2005;293(10):1223-1238.
43. Hemens BJ, Holbrook A, Tonkin M, et al. Computerized clinical decision support systems for drug prescribing and management: a decision-maker-researcher partnership systematic review. Implement Sci. 2011;6:89.
44. Roshanov PS, Fernandes N, Wilczynski JM, et al. Features of effective computerised clinical decision support systems: meta-regression of 162 randomised trials. BMJ. 2013;346:f657.
45. Kouladjian L, Gnjidic D, Chen T, Hilmer S. PP009-Development, validation and usability of software to calculate the Drug Burden Index: a pilot study. Clin Ther. 2013;35 Suppl 8:e19.
46. Faure R, Dauphinot V, Krolak-Salmon P, Mouchoux C. A standard international version of the Drug Burden Index for cross-national comparison of the functional burden of medications in older people. J Am Geriatr Soc. 2013;61(7):1227-1228.
47. Hilmer S., Gnjidic D, Abernethy DR. Drug Burden Index for international assessment of the functional burden of medications in older people. J Am Geriatr Soc. 2014;62(4):791-792.
48. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ. 1995;311(7001):376-380.
49. McLachlan AJ, Hilmer S., Le Couteur DG. Variability in response to medicines in older people: phenotypic and genotypic factors. Clin Pharmacol Ther. 2009;85(4):431-433.
50. Floroff CK, Slattum PW, Harpe SE, Taylor P, Brophy GM. Potentially inappropriate medication use is associated with clinical outcomes in critically ill elderly patients with neurological injury. Neurocrit Care. May 8, 2014. [Epub ahead of print].
51. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012; 60(4):616-631.
52. Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72-83.
53. Gallagher PF, O’Connor MN, O’Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther. 2011;89(6): 845-854.
54. Hanlon JT, Schmader KE. The Medication Appropriateness Index at 20: where it started, where it has been, and where it may be going. Drugs Aging. 2013;30(11):893-900.
55. Samsa GP, Hanlon JT, Schmader KE, et al. A summated score for the Medication Appropriateness Index: development and assessment of clinimetric properties including content validity. J Clin Epidemiol. 1994;47(8):891-896.
56. Basger BJ, Chen TF, Moles RJ. Inappropriate medication use and prescribing indicators in elderly Australians: development of a prescribing indicators tool. Drugs Aging. 2008;25(9):777-793.
57. Basger BJ, Chen TF, Moles RJ. Validation of prescribing appropriateness criteria for older Australians using the RAND/UCLA appropriateness method. BMJ Open. 2012;2(5).
58. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46(12):1481-1486.
59. Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ. 2006;332(7539): 455-459.
60. Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc. 2008;56(12):2203-2210.
61. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508-513.
62. Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D. Use of drugs with anticholinergic effect and impact on cognition in Parkinson’s disease: a cohort study. J Neurol Neurosurg Psychiatry. 2010;81(2):160-165.
63. Sittironnarit G, Ames D, Bush AI, et al. Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study. Dement Geriatr Cogn Disord. 2011;31(3):173-178.
64. Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311-320.
65. Linjakumpu T, Hartikainen S, Klaukka T, Koponen H, Kivela SL, Isoaho R. A model to classify the sedative load of drugs. Int J Geriatr Psychiatry. 2003;18(6):542-544.
66. Linjakumpu TA, Hartikainen S., Klaukka TJ, et al. Sedative drug use in the home-dwelling elderly. Ann Pharmacother. 2004;38(12): 2017-2022.
67. Sloane P, Ivey J, Roth M, Roederer M, Williams CS. Accounting for the sedative and analgesic effects of medication changes during patient participation in clinical research studies: measurement development and application to a sample of institutionalized geriatric patients. Contemp Clin Trials. 2008;29(2):140-148.
68. Boudreau RM, Hanlon JT, Roumani YF, et al. Central nervous system medication use and incident mobility limitation in community elders: the Health, Aging, and Body Composition study. Pharmacoepidemiol Drug Saf. 2009;18(10):916-922.
69. Hanlon JT, Boudreau RM, Roumani YF, et al. Number and dosage of central nervous system medications on recurrent falls in community elders: the Health, Aging and Body Composition study. J Gerontol A Biol Sci Med Sci. 2009;64(4):492-498.
70. Wright RM, Roumani YF, Boudreau R, et al. Effect of central nervous system medication use on decline in cognition in community-dwelling older adults: findings from the Health, Aging And Body Composition Study. J Am Geriatr Soc. 2009;57(2):243-250.
71. National Prescribing Service Limited. Antipsychotic Monitoring Tool. Surry Hills, Australia: 2014. Available from: http://www.nps.org.au/__data/assets/pdf_file/0015/130326/NPS_Antipsychotic_Monitoring_Tool.pdf. Accessed April 16, 2014.
72. Kersten H, Molden E, Tolo IK, Skovlund E, Engedal K, Wyller TB. Cognitive effects of reducing anticholinergic drug burden in a frail elderly population: a randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2013;68(3):271-278.
73. Lertxundi U, Domingo-Echaburu S, Hernandez R, Peral J, Medrano J. Expert-based drug lists to measure anticholinergic burden: similar names, different results. Psychogeriatrics. 2013;13(1):17-24.
74. Alldred DP. Deprescribing: a brave new word? Int J Pharm Pract. 2014;22(1):2-3.
75. Frank C. Deprescribing: a new word to guide medication review. CMAJ. 2014;186(6):407-408.
76. Woodward MC. Deprescribing: achieving better health outcomes for older people through reducing medications. J Pharm Pract Res. 2003; 33:323-328.
77. He ZK, Ball PA. Can medication management review reduce anticholinergic burden (ACB) in the elderly? Encouraging results from a theoretical model. Int Psychogeriatr. 2013;25(9):1425-1431.
78. West T, Pruchnicki MC, Porter K, Emptage R. Evaluation of anticholinergic burden of medications in older adults. J Am Pharm Assoc. 2013; 53(5):496-504.
79. Gould RL, Coulson MC, Patel N, Highton-Williamson E, Howard RJ. Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. Br J Psychiatry. 2014;204(2): 98-107.
80. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002-2012.
81. Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890-898.
82. Joester J, Vogler CM, Chang K, Hilmer SN. Hypnosedative use and predictors of successful withdrawal in new patients attending a falls clinic: a retrospective, cohort study. Drugs Aging. 2010;27(11):915-924.
83. Lonnroos E, Gnjidic D, Hilmer S., et al. Drug Burden Index and hospitalization among community-dwelling older people. Drugs Aging. 2012;29(5):395-404.
84. Lowry E, Woodman RJ, Soiza RL, Hilmer S., Mangoni AA. Drug Burden Index, physical function, and adverse outcomes in older hospitalized patients. J Clin Pharmacol. 2012;52(10):1584-1591.
85. Swannick G. Prescribing information. eMIMS (CD-ROM). St Leonards, Australia: Monthly Index of Medical Specialties.
86. Bosboom PR, Alfonso H, Almeida OP, Beer C. Use of potentially harmful medications and health-related quality of life among people with dementia living in residential aged care facilities. Dement Geriatr Cogn Dis Extra. 2012;2(1):361-371.
87. Hilmer S., Mager DE, Simonsick EM, et al. Drug Burden Index score and functional decline in older people. Am J Med. 2009;122(12): 1142-1149.
88. Kashyap M, Belleville S, Mulsant BH, et al. Methodological challenges in determining longitudinal associations between anticholinergic drug use and incident cognitive decline. J Am Geriatr Soc. 2014;62(2): 336-341.
89. Narayan SW, Hilmer S., Horsburgh S, Nishtala PS. Anticholinergic component of the Drug Burden Index and the anticholinergic drug scale as measures of anticholinergic exposure in older people in New Zealand: a population-level study. Drugs Aging. 2013;30(11):927-934.
90. Nishtala PS, Narayan S, Wang T, Hilmer SN. Associations of Drug Burden Index with falls, general practitioner visits, and mortality in older people. Pharmacoepidemiol Drug Saf. 2014;23(7):753-758.
91. Cumming RG, Handelsman D, Seibel MJ, et al. Cohort profile: the Concord Health and Ageing in Men Project (CHAMP). Int J Epidemiol. 2009;38(2):374-378.
92. Best O, Gnjidic D, Hilmer S., Naganathan V, McLachlan AJ. Investigating polypharmacy and Drug Burden Index in hospitalised older people. Intern Med J. 2013;43(8):912-918.
93. Dispennette R, Elliott D, Nguyen L, Richmond R. Drug Burden Index score and anticholinergic risk scale as predictors of readmission to the hospital. Consult Pharm. 2014;29(3):158-168.
94. Han L, McCusker J, Cole M, Abrahamowicz M, Primeau F, Elie M. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med. 2001;161(8):1099-1105.
95. Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc. 2008;56(7):1333-1341.